Brand Intelligence Graph
Company Overview
About Tune Therapeutics
Tune Therapeutics is an epigenome editing company that silences disease-causing genes without making permanent DNA cuts — a potentially safer approach than traditional gene editing for chronic diseases. The company raised $175 million in Series B financing led by Hevolution Foundation (the world's largest longevity-focused philanthropic fund), NEA, and Regeneron Ventures, and has dosed its first patient in Phase 1/2 clinical trials for Tune-401, targeting chronic hepatitis B.
Business Model & Competitive Advantage
Chronic hepatitis B (CHB) affects 296 million people globally and is not curable with existing antivirals because HBV DNA integrates into the human genome and forms covalently closed circular DNA (cccDNA) that persists indefinitely. Tune-401 simultaneously silences both integrated HBV DNA and episomal cccDNA using epigenetic writers that methylate viral promoters without cutting DNA — the first approach capable of targeting both reservoirs simultaneously.
Competitive Landscape 2025–2026
Tune's TEMPO platform can theoretically be applied to any disease where gene silencing (rather than permanent knockout) is the therapeutic objective — including oncology, inflammatory disease, and neurological conditions. The Regeneron Ventures participation provides strategic access to Regeneron's protein engineering capabilities and potential co-development agreements for combination therapies that pair TEMPO silencing with Regeneron's monoclonal antibodies.
Key Differentiators
Emerging Innovator
Tune Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Tune Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Tune Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Tune Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Tune Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →